Bladder Cancer - Results from #80

Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound. April 12, 2022

Standardized care pathways for patients with suspected urinary bladder cancer: the Swedish experience. April 11, 2022

Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy. April 8, 2022

Interactions Between Smoking and Single Nucleotide Polymorphisms Influence Urothelial Cancer Risk - Expert Commentary April 7, 2022

C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma. April 7, 2022

Diagnostic accuracy and discriminative power of biparametric versus multiparametric MRI in predicting muscle-invasive bladder cancer. April 7, 2022

Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer. April 7, 2022

The interaction between smoking and bladder cancer genetic variants on urothelial cancer risk by disease aggressiveness. April 7, 2022

Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy. April 6, 2022

Long-term Health-related Quality of Life (HRQOL) After Radical Cystectomy and Urinary Diversion - A Propensity Score-matched Analysis. April 6, 2022

Altered Urine Metabolome in Patients with Bladder Cancer - Expert Commentary April 5, 2022

Human Epidermal Growth Factor Receptor 2 (HER2) and Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations to Reveal Biological Pathways in Urothelial Carcinoma April 5, 2022

Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. April 5, 2022

The learning curve in bladder MRI using VI-RADS assessment score during an interactive dedicated training program. April 5, 2022

Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer. April 4, 2022

Cognitive function in patients undergoing cystectomy for bladder cancer - results from a prospective observational study. April 4, 2022

Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre April 1, 2022

Recurrence Mechanisms of Non-Muscle-Invasive Bladder Cancer — a Clinical Perspective April 1, 2022

Adverse pathological outcomes of patients with de novo muscle invasive bladder cancer in Northern Ontario. April 1, 2022

Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy. April 1, 2022

Page 5 of 428

email news signup